Shanda sells SRPT 21.89: The Zacks Analyst Blog Highlights:AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene
GILD-Free Report), Sarepta Therapeutics (Nasdaq:SRPT-Free Report) and Celgene Corp. (Nasdaq:CELG-Free Report). Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. Here are highlights from Wednesday's Analyst . ... ...
58 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home